

Sorrento Therapeutics, Inc.  
Form 8-K  
March 20, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): March 20, 2017**

**SORRENTO THERAPEUTICS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

|                                     |                     |                   |
|-------------------------------------|---------------------|-------------------|
| <b>Delaware</b>                     | <b>001-36150</b>    | <b>33-0344842</b> |
| <b>(State or Other Jurisdiction</b> | <b>(Commission</b>  | <b>(IRS</b>       |
| <b>of Incorporation)</b>            | <b>File Number)</b> | <b>Employer</b>   |

**Identification  
No.)**

**9380 Judicial Drive**

**San Diego, CA 92121**

**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code: (858) 210-3700**

**N/A**

**(Former Name, or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On March 20, 2017, Sorrento Therapeutics, Inc. issued the press release attached as Exhibit 99.1 to this Current Report on Form 8-K regarding its mutual understanding and resolution with respect to claims by Wildcat Capital Management LLC.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

**Exhibit Number Description**

|      |                                      |
|------|--------------------------------------|
| 99.1 | Press release, dated March 20, 2017. |
|------|--------------------------------------|

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SORRENTO THERAPEUTICS, INC.**

Date: March 20, 2017    By: /s/ Henry Ji, Ph.D.  
Name: Henry Ji, Ph.D.  
Title: President and Chief Executive Officer

**Exhibit Index**

**Exhibit Number Description**

99.1 Press release, dated March 20, 2017.